According to MacroGenics's latest financial reports the company's current revenue (TTM) is $56.91 M. In 2022 the company made a revenue of $0.14 B an increase over the years 2021 revenue that were of $76.11 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $56.91 M | -61.96% |
2022 | $0.14 B | 96.53% |
2021 | $76.11 M | -22.15% |
2020 | $97.76 M | 57.62% |
2019 | $62.02 M | 3.17% |
2018 | $60.12 M | -61.89% |
2017 | $0.15 B | 71.68% |
2016 | $91.88 M | -8.9% |
2015 | $0.10 B | 113.38% |
2014 | $47.26 M | -16.72% |
2013 | $56.75 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Pfizer PFE | $58.49 B | 102,688.61% | ๐บ๐ธ USA |
Eli Lilly LLY | $35.93 B | 63,038.46% | ๐บ๐ธ USA |
Amgen AMGN | $28.19 B | 49,434.35% | ๐บ๐ธ USA |
Gilead Sciences GILD | $27.11 B | 47,545.41% | ๐บ๐ธ USA |
Merck MRK | $60.11 B | 105,529.94% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.53 B | 79,910.54% | ๐บ๐ธ USA |
Xencor XNCR | $0.16 B | 195.80% | ๐บ๐ธ USA |